Fulcrum Therapeutics Inc (FULC)
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined diseases with significant unmet medical need in the United States. Its lead clinical-stage candidate is pociredir, a fetal hemoglobin inducer being evaluated in a phase 1b trial for sickle cell disease and beta-thalassemia. The company also maintains research programs in diamond-blackfan anemia, bone marrow failure syndromes, additional fetal hemoglobin inducers, and fibrotic disorders. Fulcrum Therapeutics has a licensing agreement with CAMP4 that covers certain small-molecule compounds, composition-of-matter and method-of-use patent rights, and related know-how for research, development, manufacturing, use, and commercialization. Incorporated in 2015, the company is headquartered in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-FULC
|
$4.93
|
32.7% Upside
|
Undervalued
|
$5.83
|
57.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-3.3x
|
0.7x
|
—
|
241.2 M
|
-79.24 M
|
2.4%
|
63.0%
|
28.0
|
—
|
83.9%
|
